Recent News
Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.Read Article
ACR Recommends QOL Self-Management Strategies
ACR
American College of Rheumatology (ACR) experts identified research suggesting that patient self-management is not as prevalent as it should or could be despite the improvements patients experience when implemented.
Read Article
CA-125 & PET/CT screening in 1432 myositis. 125 pts had CA-125 w/in 5yrs of onset - 3.1% false-positives (fibroids, endometriosis) & 14.3% false-negatives. 139 had PET done- 5.5% false-positives (LN, lung nodules), 28.6% false-negatives (missed melanoma, breast or prostate CA)… https://t.co/16KSDmp9Kz https://t.co/6QFl4jhDxp
Dr. John Cush @RheumNow ( View Tweet)
French retrospective study of 181 hemodialysis pts (97 on urate Rx-90% allopurinol, 9% febuxostat). W/ ULT pts had significantly fewer agout flare (HR:0.42; CI 95: 0.25-0.71). Overall flares 35% (23% ULT vs 50% w/o ULT; p 0.0002) https://t.co/9hTgsR2Kx9 https://t.co/Bef0T1po2c
Dr. John Cush @RheumNow ( View Tweet)
Linger on the Fingers (9.6.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. This week with a focus on fingers and better prescriptive follow through.
https://t.co/c9yvRjE9av https://t.co/mdN37AWHjX
Dr. John Cush @RheumNow ( View Tweet)
Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi https://t.co/PtxRsTifi1
Dr. John Cush @RheumNow ( View Tweet)
post hoc analysis of 4432 pt COLCORONA trial, showed colchicine had few drug interactions, none serious. The most common were interactions w/ rosuvastatin & atorvastatin (10-12% of all pts), that MAY nonsignificantly increase colchicine exposure https://t.co/W3JXne0ywH https://t.co/dNz6NVYjUW
Dr. John Cush @RheumNow ( View Tweet)
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/givt90C0tE https://t.co/3oN5qUHpUU
Dr. John Cush @RheumNow ( View Tweet)
Moving Forward on RA Prevention Trials
Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.
Read Article
Conservative Treatment of Acute Vertebral Fractures
A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term benefits were superior for teriparatide compared to bisphosphonates.
Read Article
Animal model shows Aggregatibacter actinomycetemcomitans periodontitis can trigger macrophage/caspase-11/inflammasome activation leading to paw swelling in mice anti-collagen antibody-induced arthritis (CAIA) model https://t.co/0bui2Putob https://t.co/VePVsbffDI
Dr. John Cush @RheumNow ( View Tweet)
CAR-T Like Effects with Bispecific Teclistamab
A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody… https://t.co/uE7QEHc0nx https://t.co/UcenZHv35O
Dr. John Cush @RheumNow ( View Tweet)
Does Rheumatoid Factor Influence Anti-TNF Responses in RA?
Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated… https://t.co/Ux9gHXcGbv https://t.co/gpcuWrqVHi
Dr. John Cush @RheumNow ( View Tweet)
REAL-HLH, a retrospective study of emapalumab (anti-IFNg) was effective in Rheum (15 pts) w/ hemophagocytic lymphohistiocytosis (10 w/ Still's disease, 60% in ICU w/ refractory Dz). EMA normalized CXCL9, ANC, decr steroids & had 12 mo survival=87% https://t.co/Makx4FMDlp https://t.co/XfTWyFl7kB
Dr. John Cush @RheumNow ( View Tweet)
While Raynaud's phenomenon severity is worst at very cold temperatures, it may also worsen during very warm temperatures, presumably due to air conditioning. Based on q3mos assessments of 2243 RP pts (88% female, 82% White, mean 55 yrs https://t.co/4c0XzqHYjB https://t.co/TOn4DJP4Xi
Dr. John Cush @RheumNow ( View Tweet)
Urticarial Vasculitis Overview
Urticarial vasculitis is rare and the causes often go undiagnosed. A Medscape recent overview highlights key features in the diagnosis and management of this rare disorder.
https://t.co/TUlCw76asZ https://t.co/HwDQpsAtws
Dr. John Cush @RheumNow ( View Tweet)
Scleroderma Raynaud's May Worsen in Summer
Episodes of Raynaud's phenomenon, a common feature of systemic sclerosis (SSc, also known as scleroderma), were more severe not only at low temperatures, as one would expect, but also during summertime heat, a multinational study… https://t.co/oPbwMLobol https://t.co/DbRzWOqxGw
Dr. John Cush @RheumNow ( View Tweet)
EMA Updated overview of leflunomide (Arava) https://t.co/LbuqzDdTvf https://t.co/npfsRDdFiP
Dr. John Cush @RheumNow ( View Tweet)
Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency
The European Society of Endocrinology and Endocrine Society have jointly published a clinical guideline on the diagnosis and treatment of glucocorticoid-induced adrenal insufficiency,… https://t.co/GmQ5ypvqWP https://t.co/oab9qHpxSa
Dr. John Cush @RheumNow ( View Tweet)
Sustained Hydroxychloroquine and Cardiovascular Outcomes
A national cohort study shows that continuous use of hydroxychloroquine (HCQ) protects against cardiovascular (CV) events in patients with systemic lupus erythematosus (SLE).
https://t.co/xqB2tyzzYQ https://t.co/dlFjbgbsep
Dr. John Cush @RheumNow ( View Tweet)
Dactylitis is seen in 50% of PsA patients. Dactylitis is frequently associated with more severe PsA phenotype, often representing the initial feature of the disease. Many agents are effective but no b/tsDMARD is distinguished as being superior in dactylitis.… https://t.co/NKOXReiZYd https://t.co/Ake2fixZ40
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
Linger On The Fingers (9.6.2024)
Earlier treatment with biologics to reduce the risk of organ damage-
Running With Data (8.30.2024)
-
All In The Family (8.23.2024)
Therapeutic Updates
Earlier treatment with biologics to reduce the risk of organ damage in systemic lupus erythematosus (SLE)
Sponsored by GSK US Medical Affairs
Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of
the disease by targeting its underlying mechanisms.
Read Post
Are your patients with moderate to severe RA getting the appropriate dose?
Sponsored by Genentech, Inc
Hear experts’ roundtable discussion with Dr. Alvin Wells, Dr. Orrin Troum, Dr. Grace Wright, and Dr. Aaron Broadwell in this video sponsored by Genentech.
Read Post
